<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529451</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A2339</org_study_id>
    <nct_id>NCT00529451</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg</brief_title>
  <official_title>An Eight Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing the Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg to Ramipril 5 mg in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the efficacy, safety and tolerability of aliskiren 300
      mg, 150 mg and 75 mg when compared to ramipril 5 mg in patients with essential hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferiority of Aliskiren 300 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>To evaluate the non-inferiority of aliskiren 300 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-inferiority of Aliskiren 150 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>To evaluate the non-inferiority of aliskiren 300 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-inferiority of Aliskiren 75 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>To evaluate the non-inferiority of aliskiren 75 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Sitting Systolic Blood Pressure (msSBP)and Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to 8 Week Endpoint</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>To evaluate the change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic blood Pressure (msDBP) from baseline to 8 week endpoint on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg in patients with essential hypertension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Percentage of Patients Controlled to a Target Blood Pressure of &lt; 140/90 mmHg on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg</measure>
    <time_frame>Week 8</time_frame>
    <description>To evaluate the percentage of patients controlled to a target blood pressure of &lt; 140/90 mmHg on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Percentage of Responders on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg, Define as msDBP &lt; 90 mmHg or ≥ 10mmHg Decrease From Baseline in msDBP</measure>
    <time_frame>Week 8</time_frame>
    <description>To evaluate the percentage of responders on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg, defined as msDBP &lt; 90 mmHg or ≥ 10mmHg decrease from baseline in msDBP.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1613</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Aliskiren 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aliskiren 300 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aliskiren 150 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aliskiren 75 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramipril 5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ramipril 5 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Aliskiren</description>
    <arm_group_label>Aliskiren 300 mg</arm_group_label>
    <arm_group_label>Aliskiren 150 mg</arm_group_label>
    <arm_group_label>Aliskiren 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>comparator</description>
    <arm_group_label>Ramipril 5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have msDBP ≥ 90 mmHg and &lt; 110 mmHg at the visit immediately prior to
             Visit 3

          -  Patients must have msDBP &gt;OR= 95 mmHg and &lt; 110 mmHg at Visit 3

          -  Patients must have an absolute difference of &lt; or =10 mmHg in their mean sitting
             diastolic blood pressure (msDBP) from Visit 2 to Visit 3

        Exclusion Criteria:

          -  Severe hypertension (grade 3 WHO classification; msDBP &gt;or= 110 mmHg and/or msSBP &gt;or
             = 180 mmHg).

          -  History or evidence of a secondary form of hypertension.

          -  History of transient ischemic cerebral attack within 12 months of visit 1.

          -  Current angina pectoris requiring pharmacological therapy (other than those patients
             on a stable dose of oral or topical nitrates)

          -  Type 1 or Type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c) &gt; 8% at Visit
             1.

          -  Known or suspected contraindications to the study medications, including history of
             allergy to ramipril or other ACE Inhibitors.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Sites</name>
      <address>
        <city>China</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Sites</name>
      <address>
        <city>India</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Sites</name>
      <address>
        <city>Thailand</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>India</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2007</study_first_submitted>
  <study_first_submitted_qc>September 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <results_first_submitted>December 16, 2010</results_first_submitted>
  <results_first_submitted_qc>February 28, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 25, 2011</results_first_posted>
  <last_update_submitted>February 28, 2011</last_update_submitted>
  <last_update_submitted_qc>February 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Hypertension, Aliskiren, Ramipril</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren 300 mg</title>
          <description>Aliskiren 300 mg once daily</description>
        </group>
        <group group_id="P2">
          <title>Aliskiren 150 mg</title>
          <description>Aliskiren 150 mg once daily</description>
        </group>
        <group group_id="P3">
          <title>Aliskiren 75 mg</title>
          <description>Aliskiren 75 mg once daily</description>
        </group>
        <group group_id="P4">
          <title>Ramipril 5 mg</title>
          <description>Ramipril 5 mg once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="331"/>
                <participants group_id="P2" count="323"/>
                <participants group_id="P3" count="332"/>
                <participants group_id="P4" count="330"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="294"/>
                <participants group_id="P2" count="275"/>
                <participants group_id="P3" count="292"/>
                <participants group_id="P4" count="299"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="40"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic response</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren 300 mg</title>
          <description>Aliskiren 300 mg once daily</description>
        </group>
        <group group_id="B2">
          <title>Aliskiren 150 mg</title>
          <description>Aliskiren 150 mg once daily</description>
        </group>
        <group group_id="B3">
          <title>Aliskiren 75 mg</title>
          <description>Aliskiren 75 mg once daily</description>
        </group>
        <group group_id="B4">
          <title>Ramipril 5 mg</title>
          <description>Ramipril 5 mg once daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="331"/>
            <count group_id="B2" value="323"/>
            <count group_id="B3" value="332"/>
            <count group_id="B4" value="330"/>
            <count group_id="B5" value="1316"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="9.45"/>
                    <measurement group_id="B2" value="53.3" spread="10.53"/>
                    <measurement group_id="B3" value="52.7" spread="10.22"/>
                    <measurement group_id="B4" value="52.9" spread="9.60"/>
                    <measurement group_id="B5" value="53.2" spread="9.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="288"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="285"/>
                    <measurement group_id="B4" value="296"/>
                    <measurement group_id="B5" value="1142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="144"/>
                    <measurement group_id="B4" value="151"/>
                    <measurement group_id="B5" value="585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="188"/>
                    <measurement group_id="B4" value="179"/>
                    <measurement group_id="B5" value="731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Sitting Systolic Blood Pressure (msSBP)and Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to 8 Week Endpoint</title>
        <description>To evaluate the change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic blood Pressure (msDBP) from baseline to 8 week endpoint on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg in patients with essential hypertension.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren 300 mg</title>
            <description>Aliskiren 300 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren 150 mg</title>
            <description>Aliskiren 150 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Aliskiren 75 mg</title>
            <description>Aliskiren 75 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Ramipril 5 mg</title>
            <description>Ramipril 5 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Sitting Systolic Blood Pressure (msSBP)and Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to 8 Week Endpoint</title>
          <description>To evaluate the change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic blood Pressure (msDBP) from baseline to 8 week endpoint on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg in patients with essential hypertension.</description>
          <population>Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="318"/>
                <count group_id="O3" value="324"/>
                <count group_id="O4" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>msSBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.39" spread="0.66"/>
                    <measurement group_id="O2" value="-12.16" spread="0.67"/>
                    <measurement group_id="O3" value="-12.24" spread="0.66"/>
                    <measurement group_id="O4" value="-11.46" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>msDBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.63" spread="0.44"/>
                    <measurement group_id="O2" value="-10.04" spread="0.44"/>
                    <measurement group_id="O3" value="-10.66" spread="0.44"/>
                    <measurement group_id="O4" value="-9.19" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Percentage of Patients Controlled to a Target Blood Pressure of &lt; 140/90 mmHg on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg</title>
        <description>To evaluate the percentage of patients controlled to a target blood pressure of &lt; 140/90 mmHg on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg.</description>
        <time_frame>Week 8</time_frame>
        <population>Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren 300 mg</title>
            <description>Aliskiren 300 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren 150 mg</title>
            <description>Aliskiren 150 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Aliskiren 75 mg</title>
            <description>Aliskiren 75 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Ramipril 5 mg</title>
            <description>Ramipril 5 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Percentage of Patients Controlled to a Target Blood Pressure of &lt; 140/90 mmHg on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg</title>
          <description>To evaluate the percentage of patients controlled to a target blood pressure of &lt; 140/90 mmHg on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg.</description>
          <population>Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="318"/>
                <count group_id="O3" value="324"/>
                <count group_id="O4" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.29"/>
                    <measurement group_id="O2" value="48.11"/>
                    <measurement group_id="O3" value="45.68"/>
                    <measurement group_id="O4" value="43.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Percentage of Responders on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg, Define as msDBP &lt; 90 mmHg or ≥ 10mmHg Decrease From Baseline in msDBP</title>
        <description>To evaluate the percentage of responders on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg, defined as msDBP &lt; 90 mmHg or ≥ 10mmHg decrease from baseline in msDBP.</description>
        <time_frame>Week 8</time_frame>
        <population>Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren 300 mg</title>
            <description>Aliskiren 300 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren 150 mg</title>
            <description>Aliskiren 150 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Aliskiren 75 mg</title>
            <description>Aliskiren 75 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Ramipril 5 mg</title>
            <description>Ramipril 5 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Percentage of Responders on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg, Define as msDBP &lt; 90 mmHg or ≥ 10mmHg Decrease From Baseline in msDBP</title>
          <description>To evaluate the percentage of responders on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg, defined as msDBP &lt; 90 mmHg or ≥ 10mmHg decrease from baseline in msDBP.</description>
          <population>Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="318"/>
                <count group_id="O3" value="324"/>
                <count group_id="O4" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.89"/>
                    <measurement group_id="O2" value="59.75"/>
                    <measurement group_id="O3" value="59.57"/>
                    <measurement group_id="O4" value="53.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-inferiority of Aliskiren 300 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
        <description>To evaluate the non-inferiority of aliskiren 300 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren 300 mg</title>
            <description>Aliskiren 300 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ramipril 5 mg</title>
            <description>Ramipril 5 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inferiority of Aliskiren 300 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
          <description>To evaluate the non-inferiority of aliskiren 300 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint</description>
          <population>Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="327"/>
                <count group_id="O2" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.63" spread="0.44"/>
                    <measurement group_id="O2" value="-9.19" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin of 2.25 mm Hg</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.63</ci_lower_limit>
            <ci_upper_limit>-1.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-inferiority of Aliskiren 150 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
        <description>To evaluate the non-inferiority of aliskiren 300 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren 150 mg</title>
            <description>Aliskiren 150 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ramipril 5 mg</title>
            <description>Ramipril 5 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inferiority of Aliskiren 150 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
          <description>To evaluate the non-inferiority of aliskiren 300 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint</description>
          <population>Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="318"/>
                <count group_id="O2" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.04" spread="0.44"/>
                    <measurement group_id="O2" value="-9.19" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin of 2.25 mm Hg</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.06</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Non-inferiority of Aliskiren 75 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
        <description>To evaluate the non-inferiority of aliskiren 75 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren 75 mg</title>
            <description>Aliskiren 75 mg once daily</description>
          </group>
          <group group_id="O2">
            <title>Ramipril 5 mg</title>
            <description>Ramipril 5 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inferiority of Aliskiren 75 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
          <description>To evaluate the non-inferiority of aliskiren 75 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint</description>
          <population>Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="324"/>
                <count group_id="O2" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.66" spread="0.44"/>
                    <measurement group_id="O2" value="-9.19" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin of 2.25 mm Hg</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.67</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <desc>One randomized patient in the Ramipril group never received blinded study medication. The subject is therefore not included in the &quot;at risk&quot; population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren 300 mg</title>
          <description>Aliskiren 300 mg once daily</description>
        </group>
        <group group_id="E2">
          <title>Aliskiren 150 mg</title>
          <description>Aliskiren 150 mg once daily</description>
        </group>
        <group group_id="E3">
          <title>Aliskiren 75 mg</title>
          <description>Aliskiren 75 mg once daily</description>
        </group>
        <group group_id="E4">
          <title>Ramipril 5 mg</title>
          <description>Ramipril 5 mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="332"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="332"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="329"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="332"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="332"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="332"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="329"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

